Industrial park Beijing E-Town Biomedical Park has invested in Mabworks Biotech, which is working on antibody drugs for cancer and Ebola.
China-based antibody drug developer Mabworks Biotech has secured $39m in series B funding from investors including industrial park Beijing E-Town Biomedical Park, China Money Network reported yesterday.
Private equity firm Shenzhen GTJA Investment Group led the round, which also featured investment manager Harvest Capital Management and healthcare-focused investment fund Mefund Capital.
Mabworks is using gene engineering to develop antibody-based drug treatments for diseases including Ebola. It currently has two product candidates in clinical trials, including a leukaemia treatment.
Mefund Capital…
